MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib

Molecular Therapy. Nucleic Acids
Paola StiusoMichele Caraglia

Abstract

Hepatocellular carcinoma (HCC) is the third cause of cancer-related deaths worldwide. Sorafenib is the only approved drug for patients with advanced HCC but has shown limited activity. microRNAs (miRs) have been involved in several neoplasms including HCC suggesting their use or targeting as good tools for HCC treatment. The purpose of this study was to identify novel approaches to sensitize HCC cells to sorafenib through miRs. miR-423-5p was validated as positive regulator of autophagy in HCC cell lines by transient transfection of miR and anti-miR molecules. miR-423-5p expression level was evaluated by real-time polymerase chain reaction (PCR) in sera collected from 39 HCC patients before and after treatment with sorafenib. HCC cells were cotreated with sorafenib and miR-423-5p and the effects on cell cycle, apoptosis, and autophagy were evaluated. Secretory miR-423-5p was upregulated both in vitro and in vivo by sorafenib treatment and its increase was correlated with response to therapy since 75% of patients in which an increase of secretory miR423-5p was found were in partial remission or stable disease after 6 moths from the beginning of therapy. HCC cells transfected with miR-423-5p showed an increase of cell percentage ...Continue Reading

References

Aug 1, 2002·Nature Genetics·Snorri S Thorgeirsson, Joe W Grisham
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Apr 15, 2005·Journal of Gastroenterology·Josep M Llovet
Aug 16, 2005·Current Opinion in Genetics & Development·Eric A Miska
Jul 25, 2006·Critical Reviews in Oncology/hematology·Alejandro FornerJordi Bruix
Aug 25, 2007·The Journal of Clinical Investigation·Diego F CalvisiSnorri S Thorgeirsson
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jul 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Patrick S MitchellMuneesh Tewari
Dec 5, 2008·The New England Journal of Medicine·Giancarlo Spinzi, Silvia Paggi
Jan 6, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Thomas YauRonnie Tung Ping Poon
Oct 30, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Yusuke YamamotoTakahiro Ochiya
Apr 1, 2010·The Journal of Biological Chemistry·Nobuyoshi KosakaTakahiro Ochiya
Jan 21, 2011·Nature·Beth LevineHerbert W Virgin
Feb 18, 2011·Gastroenterology·Sara ToffaninJosep M Llovet
May 28, 2011·British Journal of Pharmacology·Daniel CanalsYusuf A Hannun
Nov 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jian ZhouJia Fan
Feb 4, 2012·Frontiers in Genetics·Yuka Watanabe, Akio Kanai
Mar 21, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Claudia AugelloSilvano Bosari
Jul 6, 2014·Oxidative Medicine and Cellular Longevity·Paola StiusoAlessandro Federico
Jul 22, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Valentina VairaSilvano Bosari
Sep 24, 2014·Molecular Therapy. Nucleic Acids·Gabriella MissoMichele Caraglia

❮ Previous
Next ❯

Citations

Feb 28, 2016·Critical Reviews in Oncology/hematology·Yi HeqingLi Linfa
Jan 9, 2016·Critical Reviews in Clinical Laboratory Sciences·Subhadip MukhopadhyaySujit Kumar Bhutia
Jan 17, 2016·BMC Medical Genetics·Natália BertoniPatricia P Reis
Oct 13, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jianping ZhouJiangang Zhou
Aug 1, 2015·Journal of Experimental & Clinical Cancer Research : CR·Guang-jun ZhangTong Zhou
Jun 27, 2015·Experimental Neurobiology·Juhyun SongJong Eun Lee
Jul 5, 2016·Frontiers in Pharmacology·Nestor Prieto-DomínguezJosé L Mauriz
Jun 9, 2016·PloS One·Nicoletta PotenzaSusan Costantini
Jan 31, 2016·Applied and Environmental Microbiology·Susanne Kreuzer-RedmerGudrun A Brockmann
Apr 13, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Haochuan LiuQingsan Zhu
Dec 17, 2016·Oncotarget·Alice FaversaniSilvano Bosari
Jun 1, 2018·Experimental and Therapeutic Medicine·Xuebiao TangNian Yang
Aug 18, 2018·Experimental and Therapeutic Medicine·Wenzhuo JiaHongda Pan
Apr 7, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yi WanShijun Zhou
Oct 24, 2019·Medicina·Oronzo BrunettiNicola Silvestris
Nov 14, 2019·Scientific Reports·Rosalba SeneseNicoletta Potenza
Jul 2, 2020·OncoTargets and Therapy·Ting DaiQing Gong
Jun 21, 2018·Journal of Cellular Biochemistry·Jing GeXine Shi
Oct 3, 2018·World Journal of Gastroenterology : WJG·Giorgia MarisiAndrea Casadei Gardini
Aug 9, 2019·International Journal of Endocrinology·Sida ZhaoYazhuo Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Autophagy & Metabolism

Autophagy preserves the health of cells and tissues by replacing outdated and damaged cellular components with fresh ones. In starvation, it provides an internal source of nutrients for energy generation and, thus, survival. A powerful promoter of metabolic homeostasis at both the cellular and whole-animal level, autophagy prevents degenerative diseases. It does have a downside, however--cancer cells exploit it to survive in nutrient-poor tumors.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Parkinson's Disease & Autophagy (MDS)

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis